Mo. Favorov et al., IGM AND IGG ANTIBODIES TO HEPATITIS-E VIRUS (HEV) DETECTED BY AN ENZYME-IMMUNOASSAY BASED ON AN HEV-SPECIFIC ARTIFICIAL RECOMBINANT MOSAIC PROTEIN, Journal of medical virology, 50(1), 1996, pp. 50-58
To develop an enzyme immunoassay (EIA) for IgM antibody to hepatitis E
virus (HEV) (IgM anti-HEV) and IgG antibody to HEV (IgG anti-HEV), a
synthetic gene encoding several liner immuno-dominant antigenic epitop
es from HEV structural proteins was assembled as a chimeric recombinan
t mosaic protein (Mpr) with glutathione S-transferase and used as an i
mmunodiagnostic target. In addition, a neutralization confirmation tes
t was developed using individual synthetic peptides. Among 614 patient
s with acute hepatitis from 10 geographically distinct outbreaks, IgG
anti-HEV was found in 546 (88.9%), with a range of 77-100% depending o
n the outbreak. Of 130 patients tested for IgM anti-HEV, 126 (96.9%) w
ere positive. Among patients tested within 4 months of onset of jaundi
ce, 37/37 (100%) were IgG anti-HEV positive. For patients from whom se
ra were collected 1-16 days after onset of jaundice, the geometric mea
n IgG titer (GMT) was 1:47,000; the GMT increased to 1:70,710 30-40 da
ys after onset of jaundice and decreased to 1:1,778 3-4 months after t
he onset of jaundice. For patients tested 6-8 months after onset of ja
undice, 11/12 (92%) were IgG anti-HEV positive, and the GMT was 1:2,90
8. IgM anti-HEV was detected in 43/43 (100%) sera collected 1-40 days
after onset of jaundice, and the GMT for IgM anti-HEV was 1:10,000 at
that time. For sera collected 3-4 and 6-12 months after onset of jaund
ice, 7/14 (50%) and 5/12 (40%) respectively, were IgM anti-HEV positiv
e. In conclusion, an artificial mosaic protein composed of linear anti
genic epitopes from open reading frame 2 (ORF2) and ORF3 of HEV has be
en successfully applied to the development of a sensitive and specific
EIA for the detection of IgG and IgM anti-HEV activity. These assays
were used for the verification of HEV infection in outbreak settings a
nd for the diagnosis of HEV infection in sporadic cases. (C) 1996 Wile
y-Liss, Inc.